Cited 46 times since 2010 (3 per year) source: EuropePMC Neurogenetics, Volume 12, Issue 1, 1 1 2010, Pages 79-82 OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH
Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we associated this polymorphism with higher prescribed doses of all anti-Parkinsonian drugs. Between the first and fifth prescriptions for levodopa, for each minor rs622342 C allele, the prescribed doses were 0.34 defined daily dose higher (95% CI 0.064, 0.62; p=0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p=0.045).
